Related Experiment Video
Updated: May 28, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin effects revisited
P Andújar-Plata1, X Pi-Sunyer, B Laferrère
1Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain. paulaandujarplata@hotmail.com
Diabetes Research and Clinical Practice
|October 18, 2011
Summary
Metformin is a key treatment for type 2 diabetes. Emerging research suggests metformin may also reduce cancer risk, prompting further investigation into its potential antitumoral effects.
Area of Science:
- Endocrinology and Metabolism
- Oncology
- Pharmacology
Background:
- Metformin is a primary therapeutic agent for type 2 diabetes mellitus.
- Its precise mechanisms of action are not fully elucidated.
- Growing evidence suggests potential antitumoral properties.
Purpose of the Study:
- To review the established efficacy and mechanisms of metformin in diabetes treatment and prevention.
- To explore the emerging evidence for metformin's antitumoral effects.
- To synthesize findings from epidemiological, in vitro, and animal studies regarding metformin and cancer risk.
Main Methods:
- Conducted a comprehensive literature search on PubMed (1990-2011).
- Keywords included: metformin, cancer, mechanism of action, diabetes treatment, and prevention.
- Reviewed over one thousand articles focusing on metformin's efficacy, mechanisms, and antitumoral effects.
Main Results:
- Established efficacy of metformin in type 2 diabetes treatment and prevention (UKPDS, DPP).
- Identified mechanisms including reduced hepatic insulin resistance, altered bile acid metabolism, incretin release, and decreased amyloid deposits, with AMP-activated protein kinase as a key target.
- Epidemiological, in vitro, and animal studies indicate a potential association between metformin use and reduced cancer risk.
Conclusions:
- Metformin is a safe, cost-effective first-line therapy for type 2 diabetes.
- Evidence suggests a possible role for metformin in cancer risk reduction.
- Further randomized controlled trials are warranted to confirm these potential additional benefits of metformin.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.